Literature DB >> 8195928

Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin.

T Nakamura1, Y Ishizaka, M Nagao, M Hara, T Ishikawa.   

Abstract

The histological localization of the ret proto-oncogene (proto-ret) product was examined in neural crest-derived and neuronal tissues together with their neoplastic counterparts by immunohistochemistry using a polyclonal antibody. Schwann cells, neurons, sympathetic ganglia, and cells of the adrenal medulla were positive for the proto-ret product, whereas melanocytes were negative. Positive results were obtained from neural crest-derived tumours such as schwannoma (69 per cent, 11/16), neurofibroma (59 per cent, 13/22), neuroblastoma (80 per cent, 4/5), phaeochromocytoma (100 per cent, 3/3) and medullary thyroid carcinoma (100 per cent, 3/3). The antibody reacted with all of the 22 astrocytomas examined. With negative proto-ret expression in melanocytic tumours, proto-ret expression was considered to correlate with the differentiation of some lineages of neural crest-derived cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195928     DOI: 10.1002/path.1711720305

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

1.  Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression.

Authors:  S Borrego; M E Sáez; A Ruiz; O Gimm; M López-Alonso; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  1999-10       Impact factor: 6.318

2.  RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease.

Authors:  S Borrego; A Ruiz; M E Saez; O Gimm; X Gao; M López-Alonso; A Hernández; F A Wright; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

Review 3.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

4.  Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.

Authors:  M P Cosma; M Cardone; F Carlomagno; V Colantuoni
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 5.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 6.  Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.

Authors:  Samuel A Wells
Journal:  Endocr Relat Cancer       Date:  2017-11-15       Impact factor: 5.678

7.  A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients.

Authors:  Wolfgang Gartner; Ivelina Mineva; Teodora Daneva; Sabina Baumgartner-Parzer; Bruno Niederle; Heinrich Vierhapper; Michael Weissel; Ludwig Wagner
Journal:  Hum Genet       Date:  2005-04-20       Impact factor: 4.132

Review 8.  Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.

Authors:  Anna F Farago; Christopher G Azzoli
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 9.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma.

Authors:  James F Powers; Jaime M Brachold; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.